Newmed, Growth Despite COVID-19... Hiring Doors Wide Open

[Asia Economy Reporter Hyungsoo Park] Despite the impact of COVID-19, NewMed, which continues to grow steadily, announced on the 27th that it is recruiting talent in various fields including researchers at the central research institute, sales and marketing, and strategic planning.

Established in 2004, NewMed's Central Research Institute was recognized for its independently developed research and development platform technology and was designated as an "Excellent Corporate Research Institute" by the Ministry of Science and ICT last year.

Based on Korean medicine, NewMed researches and develops natural material ingredients and, leveraging over 20 years of accumulated excellent technology, developed a complex (HT042) containing Astragalus extract, an individually recognized ingredient that can help children's height growth. It also developed a complex (HT074) containing peony extract that can aid stomach health.

NewMed strives to develop natural materials with beneficial functionalities for the human body and to create high-quality, safe food products. The company was incorporated in 2003 and has maintained stable sales growth since 2016. Last year, sales increased by approximately 40% compared to the previous year. Focusing on the technological commercialization of research capabilities that can commercialize natural materials, NewMed is concentrating on securing a research and development pipeline.

The company has set a goal this year to apply for individual recognition of functional ingredients such as those that help reduce body fat and improve prostate health. The company expects quantitative growth as products containing the height growth health functional ingredient complex (HT042) with Astragalus extract continue to grow, and sellers of products with the stomach health individually recognized ingredient complex (HT074) with peony extract are beginning to launch products in earnest.

NewMed is gaining attention for its talent management vision that "a happy family makes a happy workplace for employees" and its corporate culture that pursues horizontal and free communication. Strengthening in-house welfare such as paternity leave for men and living stability fund support, it was selected as a ‘Seoul-type Small Giant Company’ favorable for young people to work in 2017.

A NewMed official said, "We are growing into a technology-intensive bio company through expanding employment of science and engineering graduates to secure regular employees and R&D research personnel, and establishing various welfare systems," adding, "We hope that capable talents will show great interest."

This content was produced with the assistance of AI translation services.